Canada · Delayed Price · Currency is CAD BioNxt Solutions Company Description
BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland.
The company provides BNT23001for the treatment of multiple sclerosis and myasthenia gravis; BNT24002 for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; BNT24005 for solid organic transplantation; and BNT24006, an oncology drug targeting chemotherapy platform and anticancer mTOR inhibitor.
It also offers diagnostic and biosensor screening tests; transdermal patches and oral dissolvable formulations; and development of psychedelic medicine to treat mental health-related medical conditions, such as depression, anxiety, addiction, and trauma-related stress disorder.
The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022.
BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
| Country | Canada |
| Founded | 2017 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Hugh A. Rogers |
Contact Details
Address: 1928 Linden Road Vancouver, BC V6M 1E7 Canada | |
| Phone | 780-818-6422 |
| Website | bionxt.com |
Stock Details
| Ticker Symbol | BNXT |
| Exchange | Canadian Securities Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA0909741062 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Hugh A. D. Rogers B.Sc., LL.B | Co-Founder, Chief Executive Officer and Director |
| Dr. Raimar Lobenberg Ph.D. | Co-Founder and Director |
| Wolfgang Probst | Co-Founder, Chief Financial Officer and Corporate Secretary |
| Dr. Florian A. Sahr | Head of Project Management |
| Dr. Wolfgang Wagner | Head of Research and Development |